Diethylcarbamazine citrate

Name: Diethylcarbamazine citrate
Brand: MedChemExpress
SKU: HY-12642
Rating: 4.5 (1 reviews)

Cat. No.: HY-12642 Purity: 98.01%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Diethylcarbamazine citrate is an orally active microfilaricidal agent used originally in onchocerciasis and lymphatic filiariasis. Diethylcarbamazine citrate reduces eosinophil trafficking to the lung tissue and exerts anti-allergic effects. Diethylcarbamazine citrate reduces serum levels of leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglycerides, and ameliorates insulin resistance without altering body, liver, or adipose tissue weights. Diethylcarbamazine citrate enhances reactive oxygen intermediate expression by polymorphonuclear neutrophils, increases lymphocyte proliferation, and inhibits actinomycetoma lesion development. Diethylcarbamazine citrate can be used for the researches of bronchial asthma, insulin resistance and infection.

For research use only. We do not sell to patients.

Diethylcarbamazine citrate Chemical Structure

CAS No. : 1642-54-2

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Diethylcarbamazine citrate:

Diethylcarbamazine In-stock
Diethylcarbamazine citrate (Standard) Get quote

1 Publications Citing Use of MCE Diethylcarbamazine citrate

•Cancer Sci. 2025 Aug;116(8):2281-2295. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

IL-6

Cellular Effect

Cell Line	Type	Value	Description	References
Vero	CC₅₀	9103 μg/mL Compound: DEC-C	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 23541646]

In Vitro

Diethylcarbamazine (0-40 mM; 60 min) citrate cross-reacts with rabbit anti-MPCA-BSA polyclonal IgG antibodies in an inhibition ELISA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Diethylcarbamazine (12 mg/kg; p.o.) citrate exerts anti-allergic effects in Ovalbumin (HY-W250978)-induced asthmatic mice, with pre-treatment with 40 mg/kg quercetin significantly potentiating these effects, as evidenced by reduced serum Th2 cytokines, BALF IgE, lung eosinophil markers, and complete resolution of histopathological lung damage^[1].
Diethylcarbamazine (12-200 mg/kg; p.o.; twice weekly; 12 weeks) citrate significantly ameliorates high-fat diet-induced insulin resistance in male Swiss mice via suppression of adipose tissue inflammation at the optimal 50 mg/kg dose, without affecting body or tissue weights, with significant reductions in serum glucose, insulin, triglycerides, proinflammatory mediators, liver cyclooxygenase activity, and NF-κBp65 nuclear translocation^[2].
Diethylcarbamazine (6 mg/kg; p.o.; daily; 1 week) citrate inhibits actinomycetoma development in BALB/c mice, with a statistically significant reduction in lesion size, and enhances cellular immune responses including neutrophil reactive oxygen intermediate production and lymphocyte proliferation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	white albino mice (6 to 8-week-old female, 18-20 g, intradermal sensitization + aerosol exposure Ovalbumin-induced asthma)^[1]
Dosage:	12 mg/kg
Administration:	p.o.;
Result:	Reduced serum IL-4 and IL-5, total BALF IgE and specific anti-ovalbumin IgE, lung tissue EPO and eotaxin2, and reduced inflammatory cell infiltration and thickened alveolar walls compared to untreated asthmatic mice. Showed no significant changes in serum IL-4, IL-5, BALF IgE, lung EPO, or eotaxin2, and similar histopathological improvement compared to DEC alone when preceded by anti-DEC antibody. Showed no significant changes in serum IL-4, IL-5, lung EPO, or eotaxin2, and partial reduction in inflammatory cell infiltration and alveolar wall thickening compared to DEC alone when preceded by 10 mg/kg Quercetin. Significantly reduced serum IL-4 and IL-5, increased IFN-γ/IL-4 ratio to near control levels, decreased total BALF IgE, and reduced inflammatory cell infiltration compared to DEC alone when preceded by 20 mg/kg and 40 mg/kg Quercetin.

Animal Model:	Swiss mice (male, 5 weeks old, initial 10 g body weight, high-fat diet-induced insulin resistance)^[2]
Dosage:	12 mg/kg; 50 mg/kg; 200 mg/kg
Administration:	p.o.; twice weekly; 12 weeks (from 6 to 18 week)
Result:	Reduced serum glucose levels at all oral glucose tolerance test time points (0, 30, 60, 120 min) with a statistically significant reduction in area under the curve at 50 mg/kg. Reduced serum triglyceride levels at 50 mg/kg. Reduced serum insulin levels and HOMA-IR score at 50 mg/kg. Reduced serum leptin levels at 50 mg/kg. Reduced serum levels of TNF-α, IL-6, and MCP-1 at 50 mg/kg. Significantly reduced liver cyclooxygenase activity at 50 mg/kg. Significantly inhibited nuclear localization of NF-κBp65 with increased cytoplasmic retention at 50 mg/kg. Showed no statistically significant reductions in serum glucose, triglycerides, insulin, HOMA-IR, leptin, TNF-α, IL-6, MCP-1, or liver cyclooxygenase activity relative to untreated high-fat diet-fed mice at 12 mg/kg and 200 mg/kg. Exhibited less potent effects on NF-κBp65 nuclear localization at 12 mg/kg and 200 mg/kg compared to 50 mg/kg. Caused no significant changes to body, adipose tissue, or liver weights at 50 mg/kg.

Animal Model:	BALB/c (male, 10-12 weeks old, 37-45 g, actinomycetoma model via footpad inoculation with Nocardia brasiliensis)^[3]
Dosage:	6 mg/kg
Administration:	p.o.; daily; 1 week
Result:	Reduced actinomycetoma lesion size with statistical significance compared to untreated infected controls. Resolved fistulae, granule discharge, hyperemia, and erythema by day 20 post-infection, and prevented mycetoma establishment through day 90. Reduced cellular infiltrate, eliminated granuloma layer formation, restored epidermal integrity, and reorganized damaged striated muscle fibers by day 28 post-infection. Enhanced polymorphonuclear neutrophil reactive oxygen intermediate production with statistical significance at day 3 post-infection. Increased lymphocyte proliferation in response to N. brasiliensis cellular crude extract with statistical significance at day 21 post-infection. Increased lymphocyte proliferation in response to concanavalin A with statistical significance at day 28 post-infection. Caused no significant changes in IgG or IgM antibody production against N. brasiliensis P24 antigen.

Clinical Trial

Molecular Weight

391.42

Formula

C₁₆H₂₉N₃O₈

CAS No.

1642-54-2

Appearance

Solid

Color

White to off-white

SMILES

O=C(N1CCN(C)CC1)N(CC)CC.O=C(CC(C(O)=O)(O)CC(O)=O)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (255.48 mM; Need ultrasonic)

DMSO : ≥ 39 mg/mL (99.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5548 mL	12.7740 mL	25.5480 mL
5 mM	0.5110 mL	2.5548 mL	5.1096 mL
10 mM	0.2555 mL	1.2774 mL	2.5548 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.01%

Select Batch:

Data Sheet (289 KB) SDS (420 KB)

COA (257 KB) HNMR (128 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Abdul-Razek N, et al. Enhancement of Anti-allergic Effect of Diethylcarbamazine Citrate in Asthmatic Mouse Model: Testing of Anti-drug Antibodies and Quercetin. Iran J Allergy Asthma Immunol. 2020 Aug 25;19(4):373-385. [Content Brief]

[2]. Abdel-Latif M. Diethylcarbamazine citrate ameliorates insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. Int Immunopharmacol. 2015 Dec;29(2):607-612. [Content Brief]

[3]. García-Hernández M, et al. Immunomodulatory effect of diethylcarbamazine in mice infected with Nocardia brasiliensis. Int Immunopharmacol. 2014;23(1):113-120. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	2.5548 mL	12.7740 mL	25.5480 mL	63.8700 mL
	5 mM	0.5110 mL	2.5548 mL	5.1096 mL	12.7740 mL
	10 mM	0.2555 mL	1.2774 mL	2.5548 mL	6.3870 mL
	15 mM	0.1703 mL	0.8516 mL	1.7032 mL	4.2580 mL
	20 mM	0.1277 mL	0.6387 mL	1.2774 mL	3.1935 mL
	25 mM	0.1022 mL	0.5110 mL	1.0219 mL	2.5548 mL
	30 mM	0.0852 mL	0.4258 mL	0.8516 mL	2.1290 mL
	40 mM	0.0639 mL	0.3194 mL	0.6387 mL	1.5968 mL
	50 mM	0.0511 mL	0.2555 mL	0.5110 mL	1.2774 mL
	60 mM	0.0426 mL	0.2129 mL	0.4258 mL	1.0645 mL
	80 mM	0.0319 mL	0.1597 mL	0.3194 mL	0.7984 mL
H₂O	100 mM	0.0255 mL	0.1277 mL	0.2555 mL	0.6387 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.